Greenwich LifeSciences, Inc. GLSI
Regular-session close
After hours · Nov 19, 4:41 PM ET
- YTD
- -5.81%
- 1 year
- +143.42%
5D +4.39 (+28.51%)
- Market cap
- 290.48M
- EPS (ttm)
- -1.63
- Shares out
- 13.14M
- Forward P/E
- -14.83
- YTD return
- -5.81%
- 1-year return
- +143.42%
- 50-day average
- 13.57
- 200-day average
- 14.65
- Volume
- 231.25K
- Avg volume
- 155.38K
- Open
- 20.54
- Previous close
- 20.58
- Day's range
- 19.39 – 20.97
- 52-week range
- 7.78 – 34.10
- Beta
- 3.32
- Price target
- 38.00 (+92.0%)
Key statistics
- Enterprise value
- 171.41M
- Price / book
- 23.30
- Free cash flow
- -3.15M
- Total cash
- 7.22M
- Return on equity
- -123.67%
- Short % of float
- 7.83%
Fundamental scorecard
4 of 25 checks passed on GLSI’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.21 | -0.20 | +0.01 | +4.76% |
| Aug 14, 2024 | Jun 1, 2024 | -0.20 | -0.20 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.20 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.20 | -0.19 | +0.01 | +5.00% |
| May 20, 2024 | Mar 1, 2024 | -0.20 | — | — | — |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 20, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 10, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Sep 1, 2021 | HC Wainwright & Co. | init | — | Buy |
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- greenwichlifesciences.com
News
Greenwich LifeSciences: Buy Due To GLSI-100 BC Population Expansion And More HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $70
12 Health Care Stocks Moving In Tuesday's Intraday Session Greenwich Lifesciences To Present Two FLAMINGO-01 Trial Abstracts At SABCS 2026
Greenwich LifeSciences Q3 EPS $(0.40) Misses $(0.30) Estimate
Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
Your note
Sign in to keep a note on GLSI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| PATEL SNEHAL | Chief Executive Officer | Purchase | Sep 25, 2024 | 5,536,100 |
| THOMPSON JAYE L | Officer | Purchase | Nov 20, 2024 | 264,148 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.66% | 350,144 | 4.26M | Sep 29, 2024 |
| Vanguard Group Inc | 2.08% | 273,525 | 3.33M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.02% | 133,550 | 1.62M | Sep 29, 2024 |
| Credit Agricole S.A. | 0.66% | 87,000 | 1.06M | Sep 29, 2024 |
| Northern Trust Corporation | 0.57% | 74,500 | 905.92K | Sep 29, 2024 |
| State Street Corporation | 0.54% | 71,408 | 868.32K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.17% | 153,459 | 1.87M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.08% | 141,696 | 1.72M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.54% | 71,311 | 867.14K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.47% | 61,696 | 750.22K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.39% | 50,661 | 616.04K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.25% | 32,217 | 391.76K | Oct 30, 2024 |
